➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Baxter
McKinsey
AstraZeneca

Last Updated: March 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARANESP

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ARANESP

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00093015 Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) Completed Amgen Phase 3 2004-08-01 The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus. Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD
NCT00111995 Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis Completed Amgen Phase 4 2002-05-01 This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.
NCT00116701 Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis Completed Amgen Phase 3 2005-05-01 Treatment period 1:To demonstrate that switching HD subjects with a baseline haemoglobin (Hb) ≥ 10 g/dL and ≤ 13 g/dL from either subcutaneous (SC) or intravenous (IV) rHuEPO to IV darbepoetin alfa results in a mean Hb > 11 g/dL. Treatment Period 2:To demonstrate that switching subjects with a Hb > 11 g/dL and ≤ 13 g/dL from once weekly IV darbepoetin alfa to once every 2 weeks (Q2W) maintains the mean Hb at > 11 g/dL.
NCT00117039 A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia Completed Amgen Phase 4 2004-01-01 The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network (NCCN) guidelines).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ARANESP

Condition Name

Condition Name for ARANESP
Intervention Trials
Anemia 29
Chronic Kidney Disease 11
Kidney Disease 8
Kidney Failure, Chronic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ARANESP
Intervention Trials
Anemia 29
Kidney Diseases 28
Renal Insufficiency, Chronic 27
Kidney Failure, Chronic 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ARANESP

Trials by Country

Trials by Country for ARANESP
Location Trials
United States 201
South Africa 13
Spain 13
United Kingdom 9
Italy 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ARANESP
Location Trials
Texas 11
California 9
Virginia 8
North Carolina 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ARANESP

Clinical Trial Phase

Clinical Trial Phase for ARANESP
Clinical Trial Phase Trials
Phase 4 18
Phase 3 19
Phase 2/Phase 3 5
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ARANESP
Clinical Trial Phase Trials
Completed 36
Recruiting 6
Terminated 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ARANESP

Sponsor Name

Sponsor Name for ARANESP
Sponsor Trials
Amgen 29
Akebia Therapeutics 5
M.D. Anderson Cancer Center 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ARANESP
Sponsor Trials
Industry 56
Other 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Boehringer Ingelheim
Express Scripts
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.